Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

CONMED Corporation (NASDAQ:CNMD): Are Hedge Funds Right About This Stock?

CONMED Corporation (NASDAQ:CNMD) was in 12 hedge funds’ portfolio at the end of the fourth quarter of 2012. CNMD investors should pay attention to an increase in hedge fund sentiment of late. There were 11 hedge funds in our database with CNMD holdings at the end of the previous quarter.

In the financial world, there are plenty of gauges investors can use to monitor their holdings. Some of the most useful are hedge fund and insider trading sentiment. At Insider Monkey, our research analyses have shown that, historically, those who follow the best picks of the best investment managers can outpace the S&P 500 by a superb margin (see just how much).


Just as key, positive insider trading sentiment is another way to parse down the financial markets. Obviously, there are a number of motivations for an upper level exec to drop shares of his or her company, but only one, very clear reason why they would behave bullishly. Many academic studies have demonstrated the valuable potential of this method if shareholders understand where to look (learn more here).

Keeping this in mind, we’re going to take a peek at the latest action surrounding CONMED Corporation (NASDAQ:CNMD).

Hedge fund activity in CONMED Corporation (NASDAQ:CNMD)

In preparation for this year, a total of 12 of the hedge funds we track were long in this stock, a change of 9% from one quarter earlier. With hedgies’ sentiment swirling, there exists a select group of key hedge fund managers who were increasing their holdings considerably.

Of the funds we track, James E. Flynn’s Deerfield Management had the most valuable position in CONMED Corporation (NASDAQ:CNMD), worth close to $17 million, comprising 0.9% of its total 13F portfolio. Coming in second is Cliff Asness of AQR Capital Management, with a $12 million position; the fund has 0.1% of its 13F portfolio invested in the stock. Remaining hedgies with similar optimism include Mario Gabelli’s GAMCO Investors, Chuck Royce’s Royce & Associates and Joel Greenblatt’s Gotham Asset Management.

As industrywide interest jumped, some big names have jumped into CONMED Corporation (NASDAQ:CNMD) headfirst. Citadel Investment Group, managed by Ken Griffin, created the most valuable position in CONMED Corporation (NASDAQ:CNMD). Citadel Investment Group had 1 million invested in the company at the end of the quarter. Paul Tudor Jones’s Tudor Investment Corp also made a $0 million investment in the stock during the quarter. The only other fund with a new position in the stock is Ken Gray and Steve Walsh’s Bryn Mawr Capital.

What have insiders been doing with CONMED Corporation (NASDAQ:CNMD)?

Bullish insider trading is best served when the company in question has seen transactions within the past half-year. Over the latest six-month time frame, CONMED Corporation (NASDAQ:CNMD) has experienced zero unique insiders purchasing, and 10 insider sales (see the details of insider trades here).

With the returns shown by the aforementioned studies, retail investors should always watch hedge fund and insider trading activity, and CONMED Corporation (NASDAQ:CNMD) applies perfectly to this mantra.

Click here to learn more about Insider Monkey’s Hedge Fund Newsletter

Insider Monkey’s small-cap strategy returned 29.2% between September 2012 and February 2013 versus 8.7% for the S&P 500 index. Try it now by clicking the link above.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!